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ABSTRACT
The effect of the plant-derived nonpsychotropic cannabinoid, cannabidiol (CBD), on the function of hydroxytryptamine (5-HT)3A receptors expressed in Xenopus laevis oocytes was investigated using two-electrode voltage-clamp
techniques. CBD reversibly inhibited 5-HT (1 M)-evoked
currents in a concentration-dependent manner (IC50 ⫽ 0.6
M). CBD (1 M) did not alter specific binding of the 5-HT3A
antagonist [3H]3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol-3-yl)propan-1-one (GR65630), in oocytes expressing
5-HT3A receptors. In the presence of 1 M CBD, the maximal
5-HT-induced currents were also inhibited. The EC50 values
were 1.2 and 1.4 M, in the absence and presence of CBD,
indicating that CBD acts as a noncompetitive antagonist of

The serotonin (5-HT)3 receptor, a member of the ligandgated ion channel family, mediates rapid and transient
membrane-depolarizing effect of 5-HT in the central and
peripheral nervous system (Yakel and Jackson, 1988). An
involvement of 5-HT3 receptors in pain transmission, mood
disorders, and drug abuse has been reported (for reviews,
see Riering et al., 2004; Faerber et al., 2007; Engleman et
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5-HT3 receptors. Neither intracellular BAPTA injection nor
pertussis toxin pretreatment (5 g/ml) altered the CBDevoked inhibition of 5-HT-induced currents. CBD inhibition
was inversely correlated with 5-HT3A expression levels and
mean 5-HT3 receptor current density. Pretreatment with actinomycin D, which inhibits protein transcription, decreased
the mean 5-HT3 receptor current density and increased the
magnitude of CBD inhibition. These data demonstrate that
CBD is an allosteric inhibitor of 5-HT3 receptors expressed in
X. laevis oocytes. They further suggest that allosteric inhibition of 5-HT3 receptors by CBD may contribute to its physiological roles in the modulation of nociception and emesis.

al., 2008). Furthermore, 5-HT3 receptor antagonists are
effective therapeutic agents for the treatment of chemotherapy-induced nausea and vomiting (Slatkin 2007;
Thompson and Lummis, 2007).
Previous studies showed that 5-HT3 receptor antagonists
and cannabinoids (CBs) produce similar pharmacological effects, such as nonopioid receptor-mediated analgesia and
antiemesis (for reviews, see Tramèr et al., 2001; Martin and
Wiley, 2004; Riering et al., 2004). In fact, synthetic ⌬9-tetrahydrocannabinol (THC), dronabinol, (Marinol), and THC analogs such as nabilone (Cesamet) are approved by the United
States Food and Drug Administration for use in chemotherapy-induced nausea and vomiting refractory to conventional

ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; THC, tetrahydrocannabinol; CB, cannabinoid; CBD, cannabidiol; WIN55,212-2, 4,5-dihydro-2methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one; CP55,940, (1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol; JWH-015, 1-propyl-2-methyl-3-(1-naphthoyl)indole; cRNA, complementary RNA; Icap,
capacitive current; Cm, membrane capacitance; PTX, pertussis toxin; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N⬘,N⬘-tetraacetic acid; ActD,
actinomycin D; MDL72222, tropanyl 3,5-dichlorobenzoate; HB, homogenization buffer; GR65630, 3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol3-yl)propan-1-one; ANOVA, analysis of variance; SR-141716A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1Hpyrazole-3-carboximide hydrochloride.
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antiemetic therapy (for reviews, see Tramèr et al., 2001;
Martin and Wiley, 2004; Slatkin, 2007).
The limitation of the therapeutic utility of THC and its
above-mentioned chemical analogs is the potential development of psychoactive effects through central nervous system
CB1 receptor. Cannabidiol (CBD) is one of the most abundant
cannabinoids of Cannabis sativa, with reported antioxidant,
anti-inflammatory, and antiemetic effects. It is well tolerated
and is without side effects when chronically administered to
humans (for reviews, see Mechoulam et al., 2007; Izzo et al.,
2009; Scuderi et al., 2009). Furthermore, CBD is devoid of
psychoactive properties due to a low affinity for the CB1 and
CB2 receptors (Mechoulam et al., 2007; Izzo et al., 2009;
Pertwee, 2009). Thus, pharmaceutical interest in this compound has risen significantly in recent years (Izzo et al.,
2009; Pertwee, 2009; for review, see Scuderi et al., 2009).
The effects of THC; synthetic cannabinoid receptor agonists
such as WIN55,212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin6-one], CP55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol], and JWH-015
[1-propyl-2-methyl-3-(1-naphthoyl)indole] (Fan, 1995; Barann et
al., 2002); and the endocannabinoid anandamide (Oz et al., 1995,
2002a; Barann et al., 2002; Xiong, 2008) on the functional properties of 5-HT3 receptors have been shown in previous in vitro studies. However, whether nonpsychotropic cannabinoids such as cannabidiol affect 5-HT3A receptor function is unknown. In the
present study, we have tested the hypothesis that CBD may produce its pharmacological effects, at least in part, via 5-HT3 receptors. For this purpose, the complementary RNA (cRNA) encoding
the mouse 5-HT3 subunit A of the receptor was expressed in
Xenopus laevis oocytes, and the effect of CBD on receptor function
was investigated.

Materials and Methods
Mature female X. laevis frogs were purchased from Xenopus I
(Ann Arbor, MI). They were housed in dechlorinated tap water at
18°C under a 12:12-h light/dark cycle and fed beef liver at least twice
a week. Clusters of oocytes were removed surgically under tricaine
(Sigma-Aldrich , St. Louis, MO) anesthesia (0.15%), and individual
oocytes were manually dissected away in a solution containing 88
mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.8 mM MgSO4, and 10 mM
HEPES, pH 7.5. Dissected oocytes were stored 2 to 7 days in modified
Barth’s solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM
NaHCO3, 0.3 mM Ca(NO3)2, 0.9 mM CaCl2, 0.8 mM MgSO4, and 10
mM HEPES, pH 7.5, supplemented with 2 mM sodium pyruvate,
10,000 IU/l penicillin, 10 mg/l streptomycin, 50 mg/l gentamicin, and
0.5 mM theophylline. Oocytes were placed in a 0.2-ml recording
chamber and superfused at a constant rate of 3 to 5 ml/min. The
bathing solution consisted of 95 mM NaCl, 2 mM KCl, 2 mM CaCl2,
and 5 mM HEPES, pH 7.5. The amount of 5-HT3A receptor cRNA
injected into oocytes varied from 1 to 30 ng, as indicated. However,
the injection volume of diethylpyrocarbonate-treated distilled water
was kept at 30 nl throughout the experiments. The cells were impaled with two standard glass microelectrodes filled with 3 M KCl
(1–3 M⍀). The oocytes were routinely voltage-clamped at a holding
potential of ⫺70 mV using an GeneClamp-500B amplifier (Molecular
Devices, Sunnyvale, CA). Current responses were digitized by A/D
converter and analyzed using pClamp 8 (Molecular Devices) run on
an IBM PC or directly recorded on a 2400 rectilinear pen recorder
(Gould Instrument Systems Inc., Cleveland, OH). Current-voltage
curves were generated by holding each membrane potential in a
series for 50 to 60 s, followed by a return to ⫺70 mV for 5 min. Oocyte

capacitance was measured by a paired ramp method described previously (Oz et al., 2004a). In brief, voltage ramps were used to elicit
constant capacitive current, Icap, and the charge associated with this
current was calculated by the integration of Icap. Ramps had slopes of
2 V/s and durations of 20 ms and started at a holding potential of
⫺90 mV. A series of 10 paired ramps was delivered at 1-s intervals
and averaged traces were used for charge calculations. In each oocyte, the averages of five to six measurements were used to obtain
values for membrane capacitance (Cm). Currents for Icap recordings
were filtered at 20 kHz and sampled at 50 kHz. Current density was
calculated by normalizing the average of three consecutive control
currents to the oocyte capacitance.
Compounds were applied by addition to the superfusate. All
chemicals used in preparing the solutions were from SigmaAldrich. Pertussis toxin (PTX), BAPTA, actinomycin D (ActD),
5-HT, and MDL72222 [tropanyl 3,5-dichlorobenzoate] were purchased from Tocris Bioscience (Ellisville, MO). Cannabidiol was
generously provided by National Institute on Drug Abuse Drug
Supply System, National Institutes of Health (Rockville, MD).
Procedures for the injections of PTX (50 nl; 50 g/ml) or BAPTA
(50 nl; 200 mM) were performed as described previously (Oz et al.,
1998). Injections were performed 1 h before recordings using
oil-driven ultramicrosyringe pumps (Micro4; WPI, Sarasota, FL).
Stock solutions of CBD were prepared in dimethyl sulfoxide at a
concentration of 30 mM. Dimethyl sulfoxide alone did not affect
5-HT3A receptor function when added at concentrations as high as
0.2% (v/v), a concentration 2 times greater than the most concentrated application of the agents used. Electrophysiological recordings from oocytes were conducted 3 to 4 days after cRNA injections, and both control and treatment (PTX and BAPTA) groups
were recorded on the same days.
Synthesis of cRNA. The cDNA clone of the mouse and human
5-HT3A subunits were provided by Dr. David Julius (University of
California, San Francisco, San Francisco, CA) and OriGen Technologies, Inc. (Rockville, MD), respectively. cRNAs were synthesized in
vitro using a mMessage mMachine RNA transcription kit (Ambion,
Austin, TX). The quality and sizes of synthesized cRNAs were confirmed by denatured RNA agarose gels.
Radioligand Binding Studies. Oocytes were injected with 10 ng
of mouse 5-HT3A cRNA, and functional expression of the receptors
was tested by electrophysiology on day 3. Isolation of oocyte membranes were carried out by modification of a method described previously (Oz et al., 2004b). In brief, oocytes were suspended (20
l/oocyte) in a homogenization buffer (HB) containing 10 mM
HEPES, 1 mM EDTA, 0.02% NaN3, 50 g/ml bacitracin, and 0.1 mM
phenylmethylsulfonyl fluoride, pH 7.4, at 4°C on ice and homogenized using a motorized Teflon homogenizer (six strokes, 15 s each at
high speed). The homogenate was centrifuged for 10 min at 800g.
The supernatant was collected and the pellet was resuspended in HB
and recentrifuged at 800g for 10 min. Supernatants were then combined and centrifuged for 1 h at 36,000g. The membrane pellet was
resuspended in HB at the final protein concentration of 0.5 to 0.7
mg/ml and used for the binding studies.
Binding assays were performed in 500 l of 10 mM HEPES, pH
7.4, containing 50 l of oocyte preparation and 1 nM [3H]3-(5methyl-1H-imidazol-4-yl)-1-(1-methylindol-3-yl)propan-1-one
(GR65630; 58.7 Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston, MA). Nonspecific binding was determined using
100 M MDL72222. Oocyte membranes were incubated with
[3H]GR65630 in the absence and presence of CBD at 4°C for 1 h
before bound radioligand was separated by rapid filtration onto
GF/B filters (Whatman Inc. Piscataway, NJ) presoaked in 0.3%
polyethylenimine. Filters were then washed with two 5-ml washes
of ice-cold HEPES buffer and left in 3 ml of scintillation fluid for
at least 4 h before scintillation counting was conducted to determine amounts of membrane-bound radioligand.
Data Analysis. For the nonlinear curve fitting and regression
fits of the radioligand binding data, the computer software Origin
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(OriginLab Corp., Northampton, MA) was used. In functional
assays, average values were calculated as mean ⫾ S.E.M.. Statistical significance was analyzed using ANOVA or Student’s t test.
Concentration-response curves were obtained by fitting the data
to the logistic equation y ⫽ {(Emax ⫺ Emin)/(1 ⫹ [x/EC50]n)} ⫹ Emin,
where x and y are concentration and response, respectively, Emax
is the maximal response, Emin is the minimal response, EC50 is the
half-maximal concentration, and n is the slope factor.

Results
Bath application of neither 5-HT (50 M) nor CBD (10 M)
produced detectable currents in oocytes injected with diethylpyrocarbonate-treated distilled water (30 nl/oocyte; n ⫽ 6). Application of CBD (10 M) for 20 min did not affect membrane
resistance, Cm, or resting membrane potential in oocytes
injected with 3 ng of cDNA encoding the 5-HT3A receptor
(Table 1). Currents evoked by 5-HT (1 M) were maximally
inhibited by CBD within 10 to 15 min after the initiation of
CBD perfusion. After CBD washout, recovery was slow (e.g.,
20 –30 min; Fig. 1A). Time course studies assessing the effects of
25-min CBD application on the mean amplitude of 5-HT-induced currents from six oocytes are presented in Fig. 1B.
In the next series of experiments, we examined the concentration-response relationship of the CBD effects on the function of 5-HT3 receptors (Fig. 1C). The threshold concentration
for inhibition by CBD was 0.1 M, and maximal inhibition
was achieved in concentrations ranging between 10 and 30
M. The inhibition of 5-HT (1 M)-induced current by 25-min
CBD application was concentration-dependent, with an IC50
value of 0.6 ⫾ 0.1 M and a slope value of 0.9 (Fig. 1C).
Because the participation of Gi/o proteins in the signaling
of the receptors activated by the cannabinoids and certain
CBD analogs have been reported previously (Járai et al.,
1999), we tested the effect of CBD in control (distilled waterinjected) and PTX-injected oocytes expressing 5-HT3 receptors. There was no significant difference in CBD inhibition of
5-HT responses between controls and PTX-injected cells
(ANOVA: F3,18 ⫽ 130.9, P ⬍ 0.001, n ⫽ 5– 6 for the effect of
CBD compared with controls in distilled water-injected and
PTX-injected groups; Bonferroni test: P ⬎ 0.05 for the significance of CBD inhibition between controls and PTX group;
Fig. 2A).
Because CBD has been shown to increase intracellular
Ca2⫹ levels in neurons and glia (Drysdale et al., 2006; Ryan
et al., 2006), we investigated the effect of the Ca2⫹ chelator
BAPTA on CBD inhibition of 5-HT responses. In oocytes
injected with BAPTA, the inhibition of 5-HT responses by 20
min CBD application was not significantly different from
controls (ANOVA: F3,20 ⫽ 110.7, P ⬍ 0.001, n ⫽ 5–7 for the
effect of CBD compared with controls in distilled water-injected and PTX-injected groups; Bonferroni test: P ⬎ 0.05 for
the significance of CBD inhibition between distilled waterinjected and PTX-injected group; Fig. 2B).
TABLE 1
Effects of cannabidiol (10  M) on the passive membrane properties of
the X. laevis oocytes expressing 5-HT3 receptors

Control (n ⫽ 11)
20-min CBD (n ⫽ 9)

Rm

Cm

Vm

M⍀

nF

mV

1.1 ⫾ 0.3
1.4 ⫾ 0.3

193 ⫾ 17
197 ⫾ 14

⫺35.2 ⫾ 3.4
⫺36.9 ⫾ 3.8

Rm, membrane resistance; Vm resting membrane potential.

Fig. 1. Effect of cannabidiol on 5-HT3 receptor-mediated ion currents.
A, records of currents activated by 1 M 5-HT in control (left), coapplication of 1 M CBD and 5-HT after 20-min CBD application (middle), and
30-min recovery (right). B, time course of the effect of CBD application (25
min) on the maximal amplitudes of the currents induced by 1 M 5-HT at
5-min intervals. Data points represent means ⫾ S.E.M. of six cells.
C, concentration-response curve for cannabidiol inhibition of 5-HT3 receptor-mediated ion currents. For all concentrations used, CBD was
applied for 25 min. Data points are the mean ⫾ S.E.M. (n ⫽ 6 –7); error
bars not visible are smaller than the size of the symbols. The curve is the
best fit of the data to the logistic equation described under Materials and
Methods. The IC50 value for CBD was 0.6 ⫾ 0.1 M, with a slope value
of 0.9.

Examination of the voltage dependence of the CBD inhibition indicated that the degree of inhibition of the 5-HT (1
M)-induced currents did not vary with membrane potential
(Fig. 2C). In addition, there was no change of the reversal
potential of the 5-HT-activated ion currents [control: 2 ⫾ 2
mV in controls; CBD (1 M): 4 ⫾ 3 mV], indicating that
neither the ion selectivity of the channel nor the driving force
on Na⫹ and Ca2⫹ was affected by CBD. Moreover, quantitative evaluation of data for the inhibitory effect of CBD at
different membrane potentials (Fig. 2D) showed no statistically significant differences on the effect of CBD at different
holding potentials (among ⫺20, ⫺40, ⫺60, and ⫺80 mV
groups; ANOVA: F3,16 ⫽ 0.11, P ⫽ 0.953, n ⫽ 5 for each
group).
By definition, an open channel blockade requires the opening of the channel by the binding of the agonist to the recep-
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Fig. 2. Effects of pertussis toxin treatment, calcium chelator, BAPTA
injection, and membrane potential changes on cannabidiol inhibition of
5-HT3 receptor-mediated ion currents. A, bar presentation of the effects of
1 M CBD application (20 min) on the maximal amplitudes of 5-HTinduced currents in oocytes injected with 50 nl of distilled water (controls;
n ⫽ 6) or 50 nl of PTX (50 g/ml; n ⫽ 5). Bars represent the means ⫾
S.E.M. B, bar presentation of the effects of 1 M CBD application (20
min) on the maximal amplitudes of 5-HT-induced currents in oocytes
injected with 50 nl of distilled water, controls (n ⫽ 5) or BAPTA (50 nl;
200 mM; n ⫽ 7). Bars represent the means ⫾ S.E.M. C, current-voltage
relationship of 5-HT-activated current in the absence (open circles) and
presence (closed circles) of 1 M CBD. Currents were activated by 1 M
5-HT in the same oocyte. D, percentage inhibition of 5-HT-activated
current by 1 M CBD at different membrane potentials; there are no
significant differences among these values at different membrane potentials (ANOVA: P ⬎ 0.05; n ⫽ 5).

tor. Thus, in the absence of an agonist, the degree of blockade
should be related to the frequency of channel activation.
Therefore, the extent of CBD inhibition of the 5-HT3A receptors was compared in cells exposed to 5-HT at 5-min intervals
with those exposed at 10- and 20-min intervals (Fig. 3A).
During application of 1 M CBD for 20 min, CBD was equally
effective in inhibiting currents activated at 5-, 10-, and 20min intervals (between 5-, 10-, and 20-min interval groups,
ANOVA: F2,14 ⫽ 0.29, P ⫽ 0.746, n ⫽ 5–7; Fig. 3B), indicating
that the frequency of channel opening does not alter the
extent of CBD inhibition and that the channel does not need
to be opened by the agonist for CBD to be effective. Recovery
from an open channel blocker would be facilitated by the
increases in opening frequencies. Therefore, we analyzed the
extent of recovery from CBD inhibition at different 5-HT
stimulation intervals (Fig. 3C). The recovery from CBD inhibition was not altered by 5-HT stimulation intervals, suggesting that CBD is not trapped in the channel when the
channel closes, as can occur with open channel blocking
drugs (between 5-, 10-, and 20-min interval groups, ANOVA:
F2,14 ⫽ 1.06, P ⫽ 0.379, n ⫽ 5–7).
CBD may alter 5-HT3 receptor function via competitive
inhibition of 5-HT binding to the receptor. To examine this
issue, we performed radioligand binding assays (Fig. 4, A
and B). In competition experiments, 5-HT concentrationdependently inhibited the specific binding of 1 nM

Fig. 3. Effect of 5-HT stimulation-interval alterations on the inhibition of
5-HT3A receptor-mediated responses by cannabidiol. A, time course of the
effect of CBD on the maximal amplitudes of the currents induced by 1 M
5-HT at 5- (open circles), 10- (closed circles), and 20 (closed triangles)-min
intervals. Data points represent means ⫾ S.E.M of five to seven cells.
B, percentage of CBD inhibition on the 5-HT3A receptor-mediated currents recorded at the end of a 20-min application period was not different
among oocytes stimulated with 5-HT application at 5-, 10-, and 20-min
intervals (ANOVA: P ⬎ 0.05; n ⫽ 5–7). C, percentage of controls (recovery) from CBD inhibition of the 5-HT3A receptor-mediated currents recorded at the end of a 20-min recovery period was not different between
oocytes stimulated and not stimulated with 5-HT application every 10
min (ANOVA: P ⬎ 0.05; n ⫽ 5–7). Duration of CBD application (20 min)
is indicated by the horizontal bar in the figure.

[3H]GR65630 (Fig. 4A). The concentration-dependent inhibition of [3H]GR65630 binding by 5-HT was not altered by
1 M CBD (Fig. 4A). The IC50 value in the absence and
presence of CBD was 0.7 ⫾ 0.3 and 0.6 ⫾ 0.2 M, respectively (Student’s t test: t ⫽ 1.2, df ⫽ 17, P ⫽ 0.24, n ⫽
8 –11). Likewise, increasing CBD concentrations did not
reduce specific [3H]GR65630 binding to membranes of oocytes expressing 5-HT3A receptor cDNA (Fig. 4B).
In oocytes expressing 5-HT3A receptor, the concentrationresponse curve of 5-HT was examined in the absence and
presence of 1 M CBD. The EC50 value (mean ⫾ S.E.M.) in
the absence and presence of CBD was 1.2 ⫾ 0.2 and 1.4. ⫾ 0.1
M, respectively (Student’s t test: t ⫽ ⫺0.96, df ⫽ 7, P ⫽ 0.36,
n ⫽ 4 –5). As shown in Fig. 4C, CBD did not significantly
alter EC50 values and inhibited the maximal 5-HT-responses
to the same percentage of control values (n ⫽ 5), suggesting
that CBD inhibits 5-HT-activated ion currents in a noncompetitive manner.
Because our experiments were conducted using mouse
5-HT3A receptor cRNA, we compared the effect of 1 M
CBD on the function of mouse and human 5-HT3A receptors expressed in X. laevis oocytes (3 ng of cRNA/oocyte).
Application of CBD for 20 min caused a significant inhibition of currents induced by 1 M 5-HT. The magnitude of
CBD inhibition did not differ between mouse (61 ⫾ 4%
inhibition; n ⫽ 5) and human 5-HT3A receptors (65 ⫾ 5%
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Fig. 4. Effects of cannabidiol and 5-HT on the specific binding of
[3H]GR65630 and the effect of cannabidiol on 5-HT concentration-response curves from X. laevis oocytes expressing 5-HT3A
receptors. A, inhibition of specific [3H]GR65630 binding by nonlabeled 5-HT in membranes after 1-h preincubation with 1 M
cannabidiol. The concentration of [3H]GR65630 was 1 nM. The
inhibition curve shows pooled data from 8 to 11 measurements
from three experiments. B, effects of increasing concentration of
cannabidiol on the specific binding of [3H]GR65630. Experiments were conducted in the presence of 1 nM [3H]GR65630.
The results present data from 9 to 11 measurements. Data
points indicate mean ⫾ S.E.M. C, concentration-response curves
for 5-HT-activated current in the absence (open circles) and
presence (closed circles) of 1 M CBD. Currents were activated
by 5-HT concentrations ranging from 0.1 to 100 M. Cannabidiol was applied for 20 min, and 5-HT and CBD were then
coapplied for 10 to 15 s. Data points are the mean ⫾ S.E.M. (n ⫽
4–5); error bars are not visible are smaller than the size of the
symbols. The curve is the best fit of the data to the logistic
equation described in the methods. The control concentrationresponse curve is normalized to the maximal response. The CBD
concentration-response curve is the percentage of the maximal
control. D, comparison of the 1 M CBD effect on the mouse and
human 5-HT3A receptors expressed in oocytes (3 ng/oocyte, recorded on postinjection day 3). Bar graph shows average inhibition (mean ⫾ S.E.M.) of 5-HT (1 M)-induced currents by 20min CBD application in five oocytes expressing mouse 5-HT3A
receptors and seven oocytes expressing 5-HT3A receptors.

inhibition; n ⫽ 7; Student’s t test: t ⫽ ⫺0.63, df ⫽ 10, P ⫽
0.54, n ⫽ 5–7; Fig. 4D).
In a recent study, it was demonstrated that the magnitude
of inhibition induced by the endocannabinoid anandamide is
inversely correlated with the amount of 5-HT3 receptor cRNA
injected into X. laevis oocytes (Xiong et al., 2008). For this
reason, we compared the effects of CBD on 5-HT3 receptors in
X. laevis oocytes injected with increasing concentrations of
cRNA encoding for this receptor. Increasing the concentration of 5-HT3 receptor cRNA reversed the inhibitory effect of
CBD at this receptor (Fig. 5A). For example, the maximal
inhibition induced by 1 M CBD was 81 ⫾ 5% (n ⫽ 6) in
oocytes injected with 1 ng of 5-HT3A receptor cRNA, whereas
the maximal inhibition was only 11 ⫾ 3% (n ⫽ 5) in oocytes
injected with 30 ng of 5-HT3A receptor cRNA. These values

were significantly different (Student’s t test: t ⫽ ⫺12.8, df ⫽
9, P ⬍ 0.001, n ⫽ 5– 6; Fig. 5B). The IC50 values of CBD
inhibition differed by nearly 230-fold between oocytes previously injected with 1 and 30 ng of cRNAs (Fig. 5C); the IC50
values for CBD inhibition were 121 ⫾ 11 nM, 587 ⫾ 62 nM,
and 29 ⫾ 4 M (means ⫾ S.E.M.) in cells injected with 1, 3,
and 30 ng of cRNA, respectively (Student’s t test: t ⫽ ⫺7.1,
df ⫽ 10, P ⬍ 0.001, n ⫽ 5–7; Fig. 5C). Likewise, the magnitude of inhibition produced by 1 M CBD was highly correlated with the amount of the cRNA injected into the oocytes
(r ⫽ ⫺0.99; Fig. 5D). As would be expected, the amplitude of
current activated by 1 M 5-HT also increased with the
amount of cRNA injected (Figs. 5 and 6A), indicating that
the levels of functional receptor expression correlate with the
amount of cRNA expressed in the oocytes. The magnitude of

Fig. 5. Cannabidiol inhibition is inversely correlated with
the amount of 5-HT3A receptor cRNA injected into X. laevis
oocytes. A, current traces demonstrating CBD inhibition of
5-HT-activated currents in cells previously injected with 1
ng (top) and 30 ng (bottom) of 5-HT3A receptor cRNAs.
B, time course of CBD inhibition of maximal currents induced by 1 M 5-HT in oocytes previously injected with 1,
3, and 30 ng of the 5-HT3A receptor cRNAs. The solid bar
indicates the duration (20 min) of 1 M CBD application.
Each data point represents mean ⫾ S.E.M. from the average of five to six cells. C, concentration-response curves of
CBD inhibition of 5-HT-activated current in oocytes injected with 1, 3, and 30 ng of 5-HT3A receptor cRNAs. The
curves were best fit to the logistic equation as described
under Materials and Methods. Each data point represents
mean ⫾ S.E. from five to seven oocytes. D, correlation
between the magnitude of inhibitory effect induced by 1 M
CBD and increasing concentrations of 5-HT3A cRNAs injected into oocytes (linear regression, r ⫽ ⫺0.99; n ⫽ 5–7).
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Fig. 6. Cannabidiol inhibition of 5-HT3A receptors is inversely correlated
with the mean current density and ActD treatment-induced decreases in
5-HT-induced currents. A, correlation between the percentage of CBD
inhibition of mean current density (MCD; linear regression, r ⫽ ⫺0.96).
B, bar graphs of average amplitude of current induced by maximal
concentration of 5-HT (30 M) with and without ActD treatment of
X. laevis oocytes expressing mouse 5-HT3A receptors. Each bar represents
mean ⫾ S.E.M. from six to eight cells. C, bar graphs represents average
percentage of CBD inhibition of 5-HT3A receptors without and with ActD
treatment. Each bar represents mean ⫾ S.E.M. from six to eight cells.
ⴱ, P ⬍ 0.05, significant difference compared with control (ANOVA).

inhibition produced by 1 M CBD was also highly correlated
with the mean current density of the receptor (r ⫽ ⫺0.96; Fig.
6A). To further confirm the relationship between receptor
expression and CBD inhibition, we pretreated oocytes for
24 h before recordings with 15 g/ml ActD, which inhibits
RNA transcription. Pretreatment with ActD significantly reduced mean current density (activated by 30 M 5-HT) from
4.9 ⫾ 0.6 to 1.6 ⫾ 0.4 nA/pF (ANOVA: F1,12 ⫽ 25.9, P ⬍ 0.001,
n ⫽ 6 – 8; Fig. 6B, right), suggesting that ActD reduces the
functional expression of 5-HT3A receptors. In contrast, ActD
significantly increased the magnitude of CBD inhibition from
48 ⫾ 4 to 81 ⫾ 6% (ANOVA: F1,12 ⫽ 18.2, P ⬍ 0.002, n ⫽ 6 – 8;
Fig. 6B, left).

Discussion
The results presented indicate that the plant-derived nonpsychoactive cannabinoid CBD inhibits the function of both
mouse and human 5-HT3 receptors expressed in X. laevis

oocytes. The inhibitory effect of CBD on 5-HT-induced currents was concentration-dependent and related to 5-HT3 receptor expression. The IC50 values varied from 121 nM to 29
M in oocytes injected with 1 to 30 ng of cRNA, respectively.
Increasing the concentration of 5-HT did not overcome CBD
inhibition of 5-HT-induced ion currents; i.e., the maximal
amplitudes of 5-HT-induced currents were also inhibited,
suggesting that CBD inhibition is noncompetitive.
CBD is a major nonpsychotropic constituent of C. sativa.
Unlike THC, it is virtually inactive at both CB1 and CB2
receptors (Pertwee, 2009; for review, see Izzo et al., 2009).
CB1 and CB2 receptors are not expressed in X. laevis oocytes
(Hejazi et al., 2006; Oz et al., 2007). Therefore, it is unlikely
that the effect of CBD on 5-HT3 receptors is mediated by the
activation of CB1 or CB2 receptors. CBD analogs such as
abnormal-cannabidiol are reported to activate non-CB1 and
non-CB2 receptor by a PTX-sensitive G protein (Járai et al.,
1999). However, CBD inhibited 5-HT3 receptor function in
PTX-treated oocytes, indicating that the PTX-sensitive receptors do not mediate the functional interaction of CBD with
the 5-HT3 receptor.
Cannabidiol increases intracellular Ca2⫹ levels in neurons
and glia (Drysdale et al., 2006; Ryan et al., 2006). However,
the magnitude of CBD inhibition of 5-HT3A currents was not
significantly altered by intracellular injection of BAPTA, a
high-affinity Ca2⫹ chelator. Furthermore, during our experiments, application of CBD in the highest concentration of
used (30 M) in this study, did not modify baseline currents,
indicating that intracellular Ca2⫹ concentration was not affected by CBD. Because Ca2⫹-activated Cl⫺ channels are
highly sensitive to intracellular levels of Ca2⫹ (for review, see
Dascal, 1987), the release of Ca2⫹ from internal stores of this
ion would be reflected by changes in holding current in voltage-clamp conditions. This was not seen. In addition, other
passive membrane properties such as membrane capacitance
and oocyte input resistance were not significantly altered
(Table 1), suggesting that CBD, at the concentrations used in
this study, also did not disrupt the integrity of the lipid
membrane.
CBD suppresses nausea and vomiting in animal models.
In shrews, pretreatments with CBD suppress lithium chloride-induced vomiting (Parker et al. 2004). In rats, CBD
interferes with nausea elicited by lithium chloride and
with conditioned nausea elicited by a flavor paired with
lithium chloride (Parker et al., 2002). Because CBD does
not activate known CB receptors (Izzo et al., 2009; Pertwee, 2009), and the effect of CBD was not reversed by the
CB1 receptor antagonist SR-141617A [N-(piperidin-1-yl)5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1Hpyrazole-3-carboximide hydrochloride], this suppression of
nausea and vomiting does not appear to be linked to activity of the CB1 or CB2 receptors (Kwiatkowska et al., 2004).
Cannabinoid receptor-independent actions of various cannabinoids on the function of 5-HT3 receptors have been demonstrated in several previous investigations (for review, see
Oz, 2006). In previous in vitro electrophysiological studies,
direct effects of the cannabinoid receptor ligands THC, anandamide, WIN55,212-2, and CP55,940 on the function of
5-HT3 receptors have been reported in both in vitro (Fan,
1995; Barann et al., 2002; Xiong et al., 2008; Oz et al. 1995,
2002) and in vivo studies (Godlewski et al., 2003; Przegalinski et al., 2005; Racz et al., 2008). Our results provide the
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first demonstration that nonpsychotropic phytocannabinoids
such as CBD also modulate the function of 5-HT3 receptors.
Commonly used doses of CBD (3–10 mg/kg) produce brain
levels of 200 nM to 3 M (Varvel et al., 2006). Therefore,
functional modulation of 5-HT3A receptors demonstrated in
this study (IC50 ⫽ 121 and 587 nM for 1- and 3-ng cRNAinjected oocytes, respectively) can mediate some of the cannabinoid receptor-independent actions of CBD. In previous
studies, direct actions of CBD on several integral membrane
proteins, including various subtypes of glycine receptors (Ahrens et al., 2009), 5-HT receptors (Russo et al., 2005), opioid
receptors (Kathmann et al., 2006), transient receptor potential channels (Bisogno et al., 2001; De Petrocellis et al., 2008;
Qin et al., 2008), and T-type Ca2⫹ channels (Ross et al.,
2008), have also been demonstrated (for a recent review, see
Izzo et al., 2009). In addition, anti-inflammatory, analgesic,
and antiepileptic actions of CBD are mediated by mechanisms independent of known cannabinoid receptors (for review, see Izzo et al., 2009).
Open-channel blockade is a widely used model to describe
the block of ligand-gated ion channels. However, this model
cannot account for the results of the present study. First, for
open channel blockers, the presence of the agonist is required
to let the blocker enter the channel after the receptor has
undergone an agonist-induced conformational change to open
the channel. In contrast to open channel blockers, preincubation of CBD caused a further inhibition (Figs. 1A and 3A),
indicating that CBD can interact with the closed state of the
5-HT3A receptor. Second, inhibition by CBD is not voltagesensitive, suggesting that the CBD binding site is not
charged and that the site is not within the transmembrane
electric field. Likewise, there was an absence of use-dependent blockade (Fig. 3A), and CBD had little effect when
coadministered with 5-HT without CBD preincubation (data
not shown). Third, recovery from CBD inhibition occurred
independent of agonist application intervals (Fig. 3C), indicating that CBD is not trapped in the channel when the
channel closes, as can occur with open channel blocking
drugs. Finally, CBD did not significantly affect the reversal
potential of 5-HT-induced currents, indicating that current
inhibition is not due to an alteration in the ion selectivity of
the channels.
Allosteric modulators alter the functional properties of ligand-gated ion channels by interacting with site(s) that are
topographically distinct from the ligand binding sites (for
review, see Onaran and Costa, 2009). In electrophysiological
studies, although the potency of the 5-HT, a natural ligand
(agonist) for this receptor, was not altered, its efficacy was
significantly inhibited by CBD, indicating that CBD did not
compete with the 5-HT binding site on the receptor. In agreement with these findings, radioligand binding studies indicated that displacement of [3H]GR65630 by 5-HT was not
significantly affected by CBD, further suggesting that CBD
does not interact with 5-HT binding site on the receptor.
These findings indicate that CBD acts as an allosteric modulator of 5-HT3 receptor. In previous studies, CBD has been
reported to be an allosteric modulator of several structurally
different ion channels (Izzo et al., 2009); i.e., CBD binds to
site(s) topographically distinct from the 5-HT binding sites
on the receptor-ion channel complex. The noncompetitive
property of the allosteric CBD inhibition puts it in an advantageous position, because the increases in concentration of
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endogenous agonist (5-HT) in synaptic cleft cannot alter the
efficacy of CBD.
It is likely that CBD, a highly lipophilic agent, first dissolves into the lipid membrane and then diffuses into a
nonannular lipid space to inhibit the ion channel-receptor
complex. Consistent with this idea, the effect of CBD on
5-HT3 receptor reached to a maximal level within 10 to 15
min of application time. Likewise, actions of several hydrophobic allosteric modulators, such as endocannabinoids (Oz
et al., 2002a; Spivak et al., 2007; Xiong et al., 2008), fatty
acids (Oz et al., 2004c), steroids (Oz et al., 2002b), and general anesthetics (Zhang et al., 1997), on ligand-gated ion
channels require 5 to 20 min to reach their maxima (for
review, see Oz, 2006), suggesting that the binding site(s) for
these allosteric modifiers is located inside the lipid membrane and require a relatively slow (in minutes) time course
to modulate the function of the receptor. It is likely that these
hydrophobic agents act as gating modifiers (for review, see
Oz, 2006), affecting the energy requirements for the gatingrelated conformational changes in ligand-gated ion channels
(Spivak et al., 2007).
It is interesting that we found an inverse correlation between the magnitude of CBD inhibition and the amount of
cRNA injected into oocytes. In a recent study, biotinylation
experiments indicated that the increase in the amount of
cRNA injected into X. laevis oocytes enhances the surface
expression of 5-HT3A receptors and attenuates the magnitude of anandamide inhibition of 5-HT3A receptor (Xiong et
al., 2008). This phenomenon has been suggested to be due to
the increased tendency of 5-HT3A receptors to desensitize at
low expression levels. Various conditions that decrease the
desensitization of the receptor also attenuate anandamide
inhibition (Xiong et al., 2008). By definition, receptors are
required to be open before their transition into a desensitized
state. However, as mentioned, in the majority of reports, the
effects of highly lipophilic substances, such as cannabinoid
receptor ligands (Barann et al., 2002; Oz et al., 2002a) and
steroids (Oz et al., 2002b), require a long (several seconds)lasting exposure time before the opening of the channel by
agonist application (for review, see Oz, 2006). Thus, it appears that cannabinoids can interact with 5-HT3A receptors
during the closed state and facilitate desensitization during
agonist activation of the receptor.
It is plausible to predict that CBD, similar to the effect of
anandamide on nicotinic acetylcholine receptors (Spivak et
al., 2007), reduces current amplitude by lowering the energy
barrier for receptors to enter a desensitized state. In addition, 5-HT3A receptor density can contribute to the freeenergy barrier required for conformational changes during a
receptor desensitization process and facilitate the effect of
CBD on the desensitization of 5-HT3A receptor. Clearly, further investigations in which receptor kinetics can be studied
in a more detailed and precise manner are required to delineate the mechanisms by which CBD affects 5-HT3A receptor
function.
In conclusion, our results indicate that CBD inhibits the
function of homomerically expressed 5-HT3A receptor by a
noncompetitive (allosteric) mechanism and that the expression level of 5-HT3A receptors significantly influences the
sensitivity of the receptor to the inhibitory effect of CBD.
These data add to a growing body of evidence (Izzo et al.,
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2009), indicating that cannabinoid-receptor-independent targets can contribute to pharmacological actions of CBD.
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